生长激素有益于诱导先天性联合垂体激素缺乏的成年患者的精子发生。

Growth Hormone Is Beneficial for Induction of Spermatogenesis in Adult Patients With Congenital Combined Pituitary Hormone Deficiency.

机构信息

National Health Commission (NHC) Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

出版信息

Front Endocrinol (Lausanne). 2022 Apr 22;13:868047. doi: 10.3389/fendo.2022.868047. eCollection 2022.

DOI:10.3389/fendo.2022.868047

PMID:35528001

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9074387/

Abstract

BACKGROUND

Gonadotropins are effective in inducing spermatogenesis in patients with congenital combined pituitary hormone deficiency (CCPHD). Data on recombinant human growth hormone(rhGH) adjuvant treatment to improve gonadotropin-induced spermatogenesis are limited.

DESIGN AND SETTING

This retrospective study included 60 male patients with CCPHD on a relatively large case series in a single center from mainland China. Twenty-nine patients who received gonadotropin therapy alone were defined as the Gn group, while 31 patients treated with a combination of rhGH and gonadotropins were defined as GH/Gn group.

RESULTS

Spermatogenesis rate was 96.77% (30/31) and 62.07% (18/29) in the GH/Gn and Gn group, respectively (P < 0.001). The time for initial sperm appearance in the GH/Gn group was shorter than in the Gn group (14 versus 23 months, P < 0.001). A higher level of serum testosterone was achieved in the GH/Gn group than in the Gn group (4.79 versus 3.38 ng/mL, P = 0.026). After adjustment for potential confounders, rhGH supplementation was an independent beneficial factor on spermatogenesis (HR = 2.294, 95% CI: 1.143-4.604, P = 0.019).

CONCLUSIONS

rhGH induces earlier spermatogenesis in patients with CCPHD, which encourages the co-treatment with rhGH and gonadotropins in CCPHD patients.

摘要

背景

促性腺激素在诱导先天性联合垂体激素缺乏症（CCPHD）患者的生精作用方面非常有效。关于重组人生长激素（rhGH）辅助治疗以改善促性腺激素诱导的生精作用的数据有限。

设计和设置

本回顾性研究纳入了中国大陆一家单中心的较大病例系列中的 60 例 CCPHD 男性患者。仅接受促性腺激素治疗的 29 例患者定义为 Gn 组，而接受 rhGH 和促性腺激素联合治疗的 31 例患者定义为 GH/Gn 组。

结果

GH/Gn 组和 Gn 组的生精率分别为 96.77%（30/31）和 62.07%（18/29）（P<0.001）。GH/Gn 组首次出现精子的时间短于 Gn 组（14 个月比 23 个月，P<0.001）。GH/Gn 组的血清睾酮水平高于 Gn 组（4.79 比 3.38ng/mL，P=0.026）。调整潜在混杂因素后，rhGH 补充是生精的独立有益因素（HR=2.294，95%CI：1.143-4.604，P=0.019）。